NCT00722358View on ClinicalTrials.gov

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Chronic Hepatitis C
Interventions
DRUG

BMS-650032

"Capsule, Oral, Q12h, 3/5 days~Panel 1: 200 mg~Panel 2: 400 mg~Panel 3: 600 mg"

DRUG

Placebo

"Capsule, Oral, Q 12h, 3/5 days~Panel 1: matching placebo~Panel 2: matching placebo~Panel 3: matching placebo"

Trial Locations (5)

21225

Parexel International Corporation, Baltimore

32809

Orlando Clinical Research Center, Orlando

78705

Central Texas Clinical Research, Austin

92801

Advanced Clinical Res Inst, Anaheim

00909

Local Institution, Santurce

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00722358 - A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects | Biotech Hunter | Biotech Hunter